Share this

KN- 048 Combination esmo

Back

CPS ≥1
CPS ≥20

References:

  1. Keytruda® SPC.
  2. MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.
  3. Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 ;394(10212):1915-1928.

CPS ≥1
CPS ≥20

References:

  1. Keytruda® SPC.
  2. MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.
  3. Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 ;394(10212):1915-1928.

ORR/DOR
CPS ≥1
CPS ≥20

References:

  1. Keytruda® SPC.
  2. MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.
  3. Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 ;394(10212):1915-1928.

References:

  1. Keytruda® SPC.
  2. MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.

NCCN
ESMO

References:

  1. Keytruda® SPC.
  2. Machiels JP, René Leemans C, Golusinski W, et al: Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.2020 ;31(11):1462-1475.

References:

  1. Keytruda® SPC.
  2. MSD DATA ON FILE KN048- 5-YEAR POSTHOC ANALYSIS SEPTEMBER 28,2022.B

SA-OHN-00027 | Exp: 30 Dec 2024.